黑色素瘤市場:KOL的洞察

本報告提供全球黑色素瘤市場相關調查，提供市場概要，以及已通過核准治療方法，開發平台趨勢，未來預測等資訊。

目錄

摘要整理

治療流程

調查目的

市售療法

• 概要
• 免疫治療
  • Opdivo/Yervoy（nivolumab/ipilimumab、Bristol Myers Squibb/Ono Pharmaceuticals）
  • Opdurag（nivolumab/leratorimab，百時美施貴寶）
  • Keytruda（pembrolizumab，默克公司）

BRAF/MEK抑制劑

• 摘要
  • 主要見解摘要
• 已上市的 BRAF/MEK 藥物
  • Tafinlar/Mekinist（達拉非尼/曲美替尼，諾華）
  • Kotelic/Zelbolav（cobimetinib/vemurafenib，羅氏）
  • Braftovi/Mektovi（encorafenib/binimetinib、Array BioPharma）

溶瘤病毒/免疫刺激劑

• 摘要
  • Imlygic（T-VEC/talimogene laherparepvec；安進）(6)

管道處理

• 摘要

免疫檢查點抑制劑

• 摘要
  • 主要見解摘要
  • Ribtayo（[cemiplimab]/fianlimab，Regeneron）
  • Keytruda（[pembrolizumab]/vivostrimab，默克公司）

重組免疫刺激劑

• 摘要
  • 主要見解摘要
  • mRNA-4157（個人化癌症疫苗，Moderna）
  • Nidruji（Bifficuffsp Alpha + Onfecuffsp Alpha，Philogen）

Toll 樣受體 9 (TLR9??) 激動劑

• 摘要
  • 主要見解摘要

免疫細胞毒性/T淋巴球刺激劑

• 摘要
  • 主要見解摘要
  • Kimtruck（Tebentasp、Immunocore/Medison Pharma）

組蛋白去乙醯化? (HDAC) 抑制劑

• 摘要
  • 主要見解摘要
  • Epidaza/Hiyasta（Tusidinostat、HUYA Bioscience International）

腫瘤浸潤淋巴球 (TIL) 細胞療法

• 主要見解摘要
  • Iovance 的 Contego TIL 療法 - PD1 難治性患者的另一種潛在選擇

附錄

Why are trials of Merck & Co's Keytruda+Moderna's personalised cancer vaccine mRNA-4157 generating particular interest amongst opinion leaders? What underpins experts' excitement about Iovance's tumour-infiltrating lymphocyte therapy Contego, and what factors do they say may limit its uptake? Do oncologists see a wider role in melanoma therapy for Immunocore/Medison Pharma's bispecific Kimmtrak? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to KOL Bulletins.

Table of Contents

Executive summary (7)

Treatment algorithm (1)

Research objectives (2)

Marketed therapies (35)

• Overview
• Immunotherapies (35)
  • Opdivo/Yervoy (nivolumab/ipilimumab; Bristol Myers Squibb/Ono Pharmaceuticals) (14)
  • Opdualag (nivolumab/relatlimab; Bristol Myers Squibb) (13)
  • Keytruda (pembrolizumab; Merck & Co.) (8)

BRAF/MEK inhibitors (9)

• Overview (3)
  • Key insights summary (2)
• Marketed BRAF/MEK drugs (6)
  • Tafinlar/Mekinist (dabrafenib/trametinib; Novartis) (1)
  • Cotellic/Zelboraf (cobimetinib/vemurafenib; Roche) (1)
  • Braftovi/Mektovi (encorafenib/binimetinib; Array BioPharma) (4)

Oncolytic viruses/immunostimulants (7)

• Overview (7)
  • Imlygic (T-VEC/talimogene laherparepvec; Amgen) (6)

Pipeline therapies

• Overview

Immune checkpoint inhibitors (12)

• Overview (12)
  • Key insights summary (2)
  • Libtayo ([cemiplimab)]/fianlimab; Regeneron) (1)
  • Keytruda ([pembrolizumab]/vibostolimab; Merck & Co.) (9)

Recombinant immunostimulants (19)

• Overview (19)
  • Key insights summary (3)
  • mRNA-4157 (personalized cancer vaccine; Moderna) (1)
  • Nidlegy (bifikafusp alfa + onfekafusp alfa; Philogen) (14)

Toll-like receptor 9 (TLR9) agonists (8)

• Overview (8)
  • Key insights summary (7)

Immunologic cytotoxicity/T lymphocyte stimulants (10)

• Overview (10)
  • Key insights summary (2)
  • Kimmtrak (tebentafusp; Immunocore/Medison Pharma) (7)

Histone deacetylase (HDAC) inhibitor (7)

• Overview (7)
  • Key insights summary (2)
  • Epidaza/Hiyasta (tucidinostat; HUYA Bioscience International) (5)

Tumour infiltrating lymphocyte (TIL) cell therapy (11)

• Key insights summary (11)
  • Iovance's Contego TIL therapy excites KOLs as another potential option in the PD1-refractory setting (8)

Appendix (4)

• KOL details (4)
  • KOLs from the USA (1)
  • KOLs from Australia/Europe (2)